Aim-listed Proteome Sciences has raised £2.5m through the placing of over 13.8m shares at a price of 18p each, the firm announced yesterday.
The company said it will use the funds from the placing to increase capacity and shorten lead times to ensure the group can “continue to meet the significant increase in demand for its biomarker services from a growing list of international clients”, as well as for general working capital purposes.
Cenkos acts as nominated adviser for the healthcare research firm, while FinnCap was broker on the placing.
Analysts at FinnCap said yesterday: “The funds enable the company to keep up the momentum on several fronts, whilst strengthening the balance sheet during negotiations with several potential licensees.”
Shares in Proteome were down by 5.29 per cent yesterday.